GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Cash Flow from Investing

Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Cash Flow from Investing : $-21,703 Mil (TTM As of Mar. 2024)


View and export this data going back to 1952. Start your Free Trial

What is Bristol-Myers Squibb Co Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Bristol-Myers Squibb Co spent $284 Mil on purchasing property, plant, equipment. It gained $0 Mil from selling property, plant, and equipment. It spent $20,053 Mil on purchasing business. It gained $241 Mil from selling business. It spent $274 Mil on purchasing investments. It gained $752 Mil from selling investments. It paid $0Mil for net Intangibles purchase and sale. And it paid $0 Mil for other investing activities. In all, Bristol-Myers Squibb Co spent $19,618 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Bristol-Myers Squibb Co Cash Flow from Investing Historical Data

The historical data trend for Bristol-Myers Squibb Co's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Cash Flow from Investing Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9,913.00 -10,859.00 -538.00 -1,062.00 -2,295.00

Bristol-Myers Squibb Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -210.00 -329.00 -410.00 -1,346.00 -19,618.00

Bristol-Myers Squibb Co Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Bristol-Myers Squibb Co's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Bristol-Myers Squibb Co's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21,703 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co  (NYSE:BMY) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Bristol-Myers Squibb Co's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-284 Mil. It means Bristol-Myers Squibb Co spent $284 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Bristol-Myers Squibb Co's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0 Mil. It means Bristol-Myers Squibb Co gained $0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Bristol-Myers Squibb Co's purchase of business for the three months ended in Mar. 2024 was $-20,053 Mil. It means Bristol-Myers Squibb Co spent $20,053 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Bristol-Myers Squibb Co's sale of business for the three months ended in Mar. 2024 was $241 Mil. It means Bristol-Myers Squibb Co gained $241 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Bristol-Myers Squibb Co's purchase of investment for the three months ended in Mar. 2024 was $-274 Mil. It means Bristol-Myers Squibb Co spent {stock_data.stock.currency_symbol}}274 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Bristol-Myers Squibb Co's sale of investment for the three months ended in Mar. 2024 was $752 Mil. It means Bristol-Myers Squibb Co gained $752 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Bristol-Myers Squibb Co's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0 Mil. It means Bristol-Myers Squibb Co paid $0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Bristol-Myers Squibb Co's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0 Mil. It means Bristol-Myers Squibb Co paid $0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Bristol-Myers Squibb Co's cash from other investing activities for the three months ended in Mar. 2024 was $0 Mil. It means Bristol-Myers Squibb Co paid $0 Mil for other investing activities.


Bristol-Myers Squibb Co Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Business Description

Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Executives
Christopher S. Boerner officer: EVP, Chief Commercial Officer 21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii director 1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge officer: SVP, Human Resources BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge officer: EVP, Chief Research Officer C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky officer: EVP, Chief Commercial Officer BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio officer: EVP & Chief Commercial Officer BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt director BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung officer: Vice President and Secretary C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees officer: SVP & Controller BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Autenried Paul Von officer: SVP, Enterp. Services & CIO BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543